Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Previous studies of glucocorticoid (GC) therapy and mortality have had inconsistent results and have not considered possible perimortal bias-a type of protopathic bias where illness in the latter stages of life influences GC exposure, and might affect the observed relationship between GC use and death. This study aimed to investigate all-cause and cause-specific mortality in association with GC therapy in patients with rheumatoid arthritis (RA), and explore possible perimortal bias. A retrospective cohort study using the primary care electronic medical records. Oral GC exposure was identified from prescriptions. Mortality data were obtained from the UK Office for National Statistics. Multivariable Cox proportional hazards regression models assessed the association between GC use models and death. Several methods to explore perimortal bias were examined. The cohort included 16,762 patients. For ever GC use there was an adjusted hazard ratio for all-cause mortality of 1.97 (95 % CI 1.81-2.15). Current GC dose of below 5 mg per day (prednisolone equivalent dose) was not associated with an increased risk of death, but a dose-response association was seen for higher dose categories. The association between ever GC use and all-cause mortality was partly explained by perimortal bias. GC therapy was associated with an increased risk of mortality for all specific causes considered, albeit to a lesser extent for cardiovascular causes. GC use was associated with an increased risk of death in RA, at least partially explained by perimortal bias. Importantly, GC doses below 5 mg were not associated with an increased risk of death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of supraphysiologic glucocorticoids (prednisone equivalent dose > 5 mg daily) has been associated with a higher risk of all-cause mortality (adjusted hazard ratio of 1.97 (95% CI 1.81-2.15) in rheumatoid arthritis patients (30), with increasing risk with higher current daily and cumulative doses (29, 31).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Estimates from these studies have to be interpreted cautiously because of potential underlying confounding factors such as underlying disease and disease severity (30).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“This association was not observed with daily glucocorticoid doses below 5 mg prednisone equivalent (30, 32).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,310
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109 · cited 1×
“Diagnoses on CPRD have been shown to have a high validity [23].”
BackgroundBaecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1383 · Cited by 696
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
Symmons, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.7.793 · Cited by 646
Self-citationHENCH, P. S. (1950) · Archives of Internal Medicine · doi:10.1001/archinte.1950.00230100002001 · Cited by 501 · cited 1×
“60 years ago [4] and is still used widely.”
BackgroundSurvival, prognosis, and causes of death in rheumatoid arthritis
Mitchell, D. M., Spitz, P. W., Young, D. Y., Bloch, D. A., McShane, D. J., & Fries, J. F. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290602 · Cited by 431
Wållberg‐Jonsson, S., Ohman, M. L., & Dahlqvist, S. R. (1997) · PubMed · Cited by 417
Adaptation and validation of the Charlson Index for Read/OXMIS coded databases
Khan, N. F., Perera, R., Harper, S., & Rose, P. W. (2010) · BMC Family Practice · doi:10.1186/1471-2296-11-1 · Cited by 396
Assessment and Control for Confounding by Indication in Observational Studies
Psaty, B. M., Koepsell, T. D., Lin, D., Weiss, N. S., Siscovick, D. S., Rosendaal, F. R., Pahor, M., & Furberg, C. D. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01603.x · Cited by 363 · cited 1×
“To explore this, a post hoc sensitivity analysis was conducted using the rule out approach [29, 30].”
MethodEffects of glucocorticoids on radiological progression in rheumatoid arthritis
Kirwan, J. R., Bijlsma, J. W., Boers, M., & Shea, B. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006356 · Cited by 346
Dixon, W. G., Abrahamowicz, M., Beauchamp, M.-E., Ray, D. W., Bernatsky, S., Suissa, S., & Sylvestre, M.-P. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200702 · Cited by 339
Self-citationListing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204021 · Cited by 295
del Rincón, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M., & Escalante, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38210 · Cited by 264 · cited 3×
“[12], which showed that doses lower than 5 and 8 mg PED, respectively, had no association with mortality risk.”
BackgroundGlucocorticoids and cardiovascular events in rheumatoid arthritis: A population‐based cohort study
Davis, J. M., Maradit Kremers, H., Crowson, C. S., Nicola, P. J., Ballman, K. V., Therneau, T. M., Roger, V. L., & Gabriel, S. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22418 · Cited by 233
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
Neovius, M., Simard, J. F., & Askling, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.133371 · Cited by 208
Carmona, L., Cross, M., Williams, B., Lassere, M., & March, L. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.10.001 · Cited by 190
Application of lag‐time into exposure definitions to control for protopathic bias
Tamim, H., Monfared, A. A. T., & LeLorier, J. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1360 · Cited by 186
HUMPHREYS, J. H., Warner, A., Chipping, J., Marshall, T., Lunt, M., Symmons, D. P. M., & Verstappen, S. M. M. (2014) · Arthritis Care & Research · doi:10.1002/acr.22296 · Cited by 166
Self-citationThomas, S. L., Edwards, C. J., Smeeth, L., Cooper, C., & Hall, A. J. (2008) · Arthritis Care & Research · doi:10.1002/art.24015 · Cited by 133
Glucocorticoids and insulin sensitivity in rheumatoid arthritis.
Dessein, P. H., Joffe, B. I., Stanwix, A. E., CHRISTIAN, B. F., & Veller, M. (2004) · PubMed · Cited by 128
CORBETT, M., DALTON, S., YOUNG, A., SILMAN, A., & SHIPLEY, M. (1993) · Rheumatology · doi:10.1093/rheumatology/32.8.717 · Cited by 123
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes.
Caplan, L., Wolfe, F., RUSSELL, A. S., & Michaud, K. D. (2007) · PubMed · Cited by 123
Mortality predictors among 263 patients with rheumatoid arthritis.
Leigh, J. P., & Fries, J. F. (1991) · PubMed · Cited by 107
Lunt, M., Watson, K. D., Dixon, W. G., British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons, D. P. M., Hyrich, K. L., & British Society for Rheumatology Biologics Register (2010) · Arthritis & Rheumatism · doi:10.1002/art.27660 · Cited by 82
Self-citationTate, A. R., Beloff, N., Al-Radwan, B., Wickson, J., Puri, S., Williams, T., van Staa, T. P., & Bleach, A. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-001847 · Cited by 73
Sihvonen, S., Korpela, M. M., Mustonen, J. T., Huhtala, H. S. A., Karstila, K., & Pasternack, A. I. (2006) · PubMed · Cited by 48
Davis, K. J., Watkins, S. E., Sampson, T., & Davis, K. J. (2011) · International Journal of COPD · doi:10.2147/copd.s14247 · Cited by 41
Pincus, T., Sokka, T., & Stein, C. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00013 · Cited by 38
Mortality in Rheumatoid Arthritis, Particularly as Regards Drug Use
Allebeck, P., Rodvall, Y., & Allander, E. (1985) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748509165491 · Cited by 17
Cited by
Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216653 · Cited by 275
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Metadata
- Authors
- Movahedi, M., Costello, R., Lunt, M., Pye, S. R., Sergeant, J. C., & Dixon, W. G.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Corresponding author
- Dixon, William Gregory
- ORCID
- Venue
- European Journal of Epidemiology
- Published
- 2016-06-02
- Volume
- 31
- Issue
- 10
- Pages
- 1045-1055
- ISSN
- 0393-2990 (ISSN-L)
- 1573-7284
- PMC
- PMC5065607
- OpenAlex
- W2418539374
- Cited by
- 58
- References
- 35
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 6 · 2018: 3 · 2017: 10
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Journal of Epidemiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, cc-by)
- Funders
- Arthritis Research UK (20380)
- Medical Research Council (G0902272)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- oral corticosteroids, rheumatoid arthritis, mortality, protopathic bias, prednisolone-equivalent dose, cause-specific mortality, cardiovascular mortality
- MeSH terms
- Administration, Oral, Arthritis, Rheumatoid, Female, Glucocorticoids, United Kingdom, Humans, Male, Middle Aged, Prednisolone, Retrospective Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


